Welcome to our dedicated page for Elite Pharmaceuticals news (Ticker: ELTP), a resource for investors and traders seeking the latest updates and insights on Elite Pharmaceuticals stock.
Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products, improving off-patent drug products, and developing generic versions of controlled release drug products with high barriers to entry. With four ANDA products partnered with Tagi Pharma, Elite is making strides in the pharmaceutical industry. Elite also manufactures Lodrane D® and receives royalties for this allergy product partnered with ECR Pharmaceuticals, a wholly owned subsidiary of Hi-Tech Pharmacal. Their lead pipeline products, Eli-216 and Eli-154, are novel sustained-release oral formulations of opioids for chronic pain treatment.
Elite Pharmaceuticals (OTCQB: ELTP) reported financial results for Q3 FY2025 ended December 31, 2024. The company saw consolidated revenues of $14.4 million, representing an 8% decrease ($1.2 million) compared to the same period last year. Operating profits declined by 69% to $1.1 million, a $2.4 million decrease from the previous year.
The company attributed the performance decline to timing differences during the December holiday period, which resulted in shipment delays into the first week of January 2025. Elite Pharmaceuticals, which specializes in developing, manufacturing, and distributing niche generic products, has scheduled a conference call for February 14, 2025, at 11:30 AM EST to discuss these results and provide business updates.
Elite Pharmaceuticals (OTCQB: ELTP), a specialty pharmaceutical company focused on niche generic products, has scheduled its Q3 FY2025 financial results release for February 13, 2025. The company will host a conference call on February 14, 2025, at 11:30 AM EST to discuss financial and operating results, along with providing a business update.
Stockholders are invited to submit questions prior to the call, with general questions due by February 12, 2025 (5:00 PM EST) and financial questions by February 13, 2025 (7:00 PM EST). The conference call will be accessible via domestic (1-800-346-7359) and international (1-973-528-0008) dial-in numbers using conference number 98840.
Elite Pharmaceuticals (OTCQB: ELTP) has launched its generic version of Vyvanse® (Lisdexamfetamine Disylate) for treating attention deficit hyperactivity disorder (ADHD). The product is available in seven different strengths: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg capsules. The generic drug will be marketed and sold under the Elite Laboratories label. According to IQVIA data, the original drug recorded annual sales of approximately $4.3 billion for the twelve months ending October 2024.
Elite Pharmaceuticals (OTCQB: ELTP) has launched its generic version of Norco® (hydrocodone bitartrate and acetaminophen tablets, USP CII) in four different strengths: 2.5mg/325mg, 5mg/325mg, 7.5mg/325mg, and 10mg/325mg. The medication is indicated for managing severe pain requiring opioid analgesics when alternative treatments are inadequate. According to IQVIA, the annual sales for this product reached approximately $300 million for the twelve months ending September 2024.
Elite Pharmaceuticals (OTCQB: ELTP) has received FDA approval for its generic version of Vyvanse (Lisdexamfetamine Dimesylate) capsules in seven different strengths ranging from 10 mg to 70 mg. The medication is designed to treat Attention Deficit Hyperactivity Disorder (ADHD). According to IQVIA data, the combined brand and generic market for this product recorded annual sales of $4.3 billion for the twelve months ending September 2024.
Elite Pharmaceuticals (OTCQB: ELTP) reported strong financial results for Q2 FY2025 ended September 30, 2024. Consolidated revenues reached $18.9 million, marking a significant 33% increase ($4.7 million) compared to the same period last year. Operating profits rose to $3.5 million, showing an impressive 84% growth ($1.6 million) year-over-year. The improved performance was primarily driven by higher sales in Elite's label product line during the quarter.
Elite Pharmaceuticals (OTCQB: ELTP), a specialty pharmaceutical company, announced it will release its second quarter financial results for fiscal year 2025 on November 14, 2024. A live conference call to discuss these results and provide a business update is scheduled for November 15, 2024, at 11:30 AM EST. Stockholders can submit questions to be addressed during the call, with general queries due by November 13 and financial questions by November 14. The call will be accessible via dial-in numbers and an audio replay will be available on the company's website.
Elite Pharmaceuticals (OTCQB: ELTP) has received approval from the Israeli Ministry of Health for its generic version of Adderall®. The product, an immediate-release mixed salt of amphetamine, will be available in 10 mg, 20 mg, and 30 mg tablets. Elite will supply the product to Dexcel Pharma, its exclusive distributor for the Israeli market.
The generic Adderall® is indicated for treating Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy. Under the agreement, Elite will manufacture and package the product under Dexcel's label, while Dexcel will handle sales, marketing, and distribution. Dexcel will pay an agreed transfer price and share profits under certain conditions. The product is jointly owned by Elite and Mikah Pharma .
The first shipment timeline depends on licensee orders, DEA quotas, and manufacturing processes, which could take months to complete.
Elite Pharmaceuticals (OTCQB: ELTP) has announced the commercial launch of its generic version of Tylenol with Codeine (acetaminophen and codeine phosphate) tablets. The product is available in three strengths: 300mg/15mg, 300mg/30mg, and 300mg/60mg. These tablets are indicated for managing mild to moderate pain where opioid treatment is appropriate and alternative treatments are inadequate.
The product is marketed and sold under the Elite Laboratories, Inc. label. According to IQVIA data, the total U.S. sales of acetaminophen and codeine in these strengths were approximately $47 million for the 12 months ended May 2024. This launch represents Elite's entry into a significant market segment for pain management medications.
Elite Pharmaceuticals (OTCQB: ELTP) has launched its generic methotrexate sodium 2.5 mg tablets. This medication is a dihydrofolate reductase inhibitor used to treat various conditions in adults and children, including acute lymphoblastic leukemia, rheumatoid arthritis, and severe psoriasis.
The product is marketed under the Elite Laboratories, Inc. label. According to IQVIA data, the total U.S. sales of methotrexate sodium 2.5 mg tablets were approximately $63 million for the 12 months ended May 2024. This launch represents Elite's entry into a significant market segment within the pharmaceutical industry.
FAQ
What is the current stock price of Elite Pharmaceuticals (ELTP)?
What is the market cap of Elite Pharmaceuticals (ELTP)?
What is Elite Pharmaceuticals, Inc. known for?
What are Elite Pharmaceuticals' lead pipeline products?
Who are Elite Pharmaceuticals' key partners?
Where is Elite Pharmaceuticals' manufacturing facility located?
What recent achievement did Elite Pharmaceuticals announce?
